3 Cash-Producing Stocks We’re Skeptical Of
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
Cash flow is valuable, but it’s not everything - StockStory helps you identify the companies that truly put it to work. Keeping that in mind, here are three cash-producing companies to avoid and some better opportunities instead.
Trailing 12-Month Free Cash Flow Margin: 6.9%
With its iconic canned soup as its cornerstone product, Campbell's (NASDAQ:CPB) is a packaged food company with an illustrious portfolio of brands.
Why Should You Sell CPB?
Declining unit sales over the past two years indicate demand is soft and that the company may need to revise its product strategy
Forecasted revenue decline of 2.6% for the upcoming 12 months implies demand will fall off a cliff
Performance over the past three years shows its incremental sales were much less profitable, as its earnings per share fell by 5.1% annually
Campbell’s stock price of $21.12 implies a valuation ratio of 9.6x forward P/E. Dive into our free research report to see why there are better opportunities than CPB.
Trailing 12-Month Free Cash Flow Margin: 8.7%
Spun off from Merck in 2021 to create a company dedicated to addressing unmet needs in women's health, Organon (NYSE:OGN) is a global healthcare company focused on improving women's health through prescription therapies, medical devices, biosimilars, and established medicines.
Why Are We Cautious About OGN?
Sales stagnated over the last five years and signal the need for new growth strategies
Falling earnings per share over the last four years has some investors worried as stock prices ultimately follow EPS over the long term
Free cash flow margin dropped by 22.6 percentage points over the last five years, implying the company became more capital intensive as competition picked up
At $6.08 per share, Organon trades at 1.8x forward P/E. Check out our free in-depth research report to learn more about why OGN doesn’t pass our bar.
Trailing 12-Month Free Cash Flow Margin: 14.5%
One of the three major credit bureaus in the United States alongside Equifax and Experian, TransUnion (NYSE:TRU) is a global information and insights company that provides credit reports, fraud prevention tools, and data analytics to help businesses make decisions and consumers manage their financial health.
Why Does TRU Give Us Pause?
Efficiency has decreased over the last five years as its operating margin fell by 3.1 percentage points
Capital intensity has ramped up over the last five years as its free cash flow margin decreased by 5 percentage points
Below-average returns on capital indicate management struggled to find compelling investment opportunities
TransUnion is trading at $70.55 per share, or 14.6x forward P/E. If you’re considering TRU for your portfolio, see our FREE research report to learn more.
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it's flagging for this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.